Indaptus Therapeutics to Present at Investor Conferences
Indaptus Therapeutics, Inc. (NASDAQ: INDP) has exciting news for investors and stakeholders, as it prepares for two significant investor conferences. The CEO, Jeffrey A. Meckler, is set to share insights into the company's innovative strategies and future goals at these gatherings.
Upcoming Conferences and Presentation Details
The first conference, known as BioFuture 2024, will span three days from October 28 to October 30. This event is taking place at Cure by Deerfield in New York City, where key players in the biotech and investment communities will converge.
BioFuture 2024 Presentation
Mr. Meckler is scheduled to deliver a presentation on October 28 at 3:30 PM ET, showcasing the latest advancements at Indaptus. The presentation will occur in Track 12 - B (12th Floor). Attendees can expect insightful discussions on the company's pioneering research and products that aim to harness the immune system's potential against various diseases.
Throughout the BioFuture conference, Mr. Meckler will also be available for one-on-one meetings, allowing interested investors the opportunity to engage directly and discuss potential collaborations or investments.
ThinkEquity Conference Participation
The second conference on the agenda is the ThinkEquity Conference, taking place on October 30 at the Mandarin Oriental Hotel, also in New York City. This conference focuses on connecting companies with potential investors and partners.
ThinkEquity Conference Presentation
During this event, Mr. Meckler will present at 12:30 PM ET, specifically in South Salon II. This session will provide further details on Indaptus’ strategic plans and how the company is positioning itself within the rapidly evolving field of immunotherapy.
Similar to BioFuture, there will be opportunities for one-on-one meetings, emphasizing Indaptus' commitment to open communication with its investors.
Insight into Indaptus Therapeutics
Indaptus Therapeutics stands at the forefront of immunotherapy research, building on a legacy of over a century of advancements in this field. The company's novel therapeutic approach focuses on activating both innate and adaptive immune responses, which are critical for effective tumor and viral responses. Utilizing a multi-targeted strategy, Indaptus aims to administer a diverse range of immune-activating signals safely via intravenous methods.
The patented technology includes unique strains of non-pathogenic Gram-negative bacteria that produce a platform of multiple agonists targeting key immune pathways, such as Toll-like receptor (TLR) and Stimulator of interferon genes (STING). This innovative design allows for reduced toxicity while maintaining robust immune activation potential.
Clinical Efficacy and Innovation
The Decoy product candidates developed by Indaptus have shown significant promise in preclinical models, effectively eradicating established tumors, including various types of carcinomas and lymphomas. Notably, the candidates have demonstrated activity against metastatic pancreatic and colorectal cancers, as well as single-agent activity in cases of established breast carcinoma.
Moreover, the combination of Decoy candidates with other therapies, including anti-PD-1 therapy and chemotherapy, has resulted in remarkable outcomes and the development of immunological memory in preclinical models, demonstrating the profound potential of this technology.
Indaptus is also exploring applications beyond cancer treatment, showcasing the efficacy of its Decoy candidates in managing chronic infections like hepatitis B and HIV.
Investor Engagement and Opportunities
Both conferences represent valuable opportunities for investors to learn more about Indaptus Therapeutics' innovative research and potential developments in immunotherapy. Interested investors are encouraged to register and schedule one-on-one meetings to explore in-depth discussions regarding the company’s future directions and investments.
For any inquiries, investors can reach out via email at investors@indaptusrx.com.
Frequently Asked Questions
What is Indaptus Therapeutics known for?
Indaptus Therapeutics is known for its innovative approach to immunotherapy, focusing on multi-targeted strategies to activate immune responses against tumors and chronic infections.
When and where will the upcoming investor presentations take place?
The upcoming investor presentations will occur at BioFuture 2024 on October 28 and at the ThinkEquity Conference on October 30 in New York City.
What can investors expect from these conferences?
Investors can expect to gain insights into Indaptus' innovative technologies, potential growth strategies, and opportunities for direct engagement with leadership through one-on-one meetings.
What is the significance of the Decoy technology?
The Decoy technology represents a groundbreaking approach in immunotherapy, showing potential effectiveness against various cancers and chronic viral infections with minimized toxicity.
How can investors get more information about Indaptus Therapeutics?
Interested investors can email investors@indaptusrx.com for more detailed information and inquiries.
